nogens of M. pneumoniae which are precipitated by convalescent, but not by acute, sera.
Materials and Methods
Organisms and Culture Conditions. Virulent, wild type M. pn~umoniae strains M 129-B 15 (22, 23) and M129-B25C (24) were used in this study. Monolayer cultures were grown in 32-oz (~960 ml) prescription bottles in Hayflick medium (25) at 37°C for 48-72 h, until the phenol red pH indicator in the growth medium became orange. The monolayers were washed four times with phosphate-buffered saline (PBS) (pH 7.2) before collection by centrifugation at 9,500 g for 15 min. For intrinsic labeling of M. pneumoniae with [3~S]methionine, log-phase cultures were washed once with PBS and pulsed for 6 h at 37°C with 250/~Ci of L-[sSS]methionine (Amersham Corp., Arlington Heights, IL) (1,050-1,400 Ci/mmol sp act) in Hanks' balanced salts solution containing 10% dialyzed horse serum. The monolayers were washed once with PBS containing 1 mM cold methionine, chased for 1.5 h at 37°C in Hayflick medium, and then washed four times with PBS containing 1 mM cold methionine before collection as above. Mycoplasmas were extrinsically labeled in suspension by a lactoperoxidase-catalyzed radioiodination procedure (3, 26) . Washed M. pneumoniae monolayers or cultures of Mycoplasma orale and Mycoplasma salivarium (provided by Dr. J. Tully) were suspended in 1 ml PBS, and 0.5 mCi carrier-free [125I] NaI (Amersham Corp.) and 50/zg lactoperoxidase (E.C. 1.11.1.7; 100 IU/mg; CalbiochemBehring Corp., San Diego, CA) were added. The radioiodination reaction was initiated by the addition of 25 /zl of 0.001% hydrogen peroxide, and 10 min later another 25-/zl aliquot of hydrogen peroxide was added. After another 10-min interval, the reaction was terminated by the addition of 5 ml phosphate-buffered iodide (PBI; similar to PBS, but with sodium iodide substituted for sodium chloride). The iodinated mycoplasmas were pelleted by centrifugation, and washed twice with PBI and once with PBS before use.
Antisera. Paired acute and convalescent human sera obtained from patients with M. pneumoniae were provided by Dr. C. Helms, University of Iowa, Iowa City, IA. These pairs of human sera were selected because they demonstrated a detectable rise in M. pneumoniae CF titer. Sequential serum samples obtained from military recruits participating in an M. pneumoniae vaccine field trial were provided by Dr. J. Tully and Dr. L. Senterfit. Only those recruits who later contracted mycoplasma pneumonia were selected for this evaluation of sequential serum response to M. pneumoniae. Control human serum samples collected from patients who did not have mycoplasma pneumonia were provided by the clinical pathology department of Medical Center Hospital, San Antonio, TX. Preinfection hamster sera were obtained by cardiac puncture of uninfected Syrian golden hamsters. Some hamsters were then intranasally inoculated (23, 27) with 108 colony-forming units (CFU) of M. pneumoniae strain B 15 and bled on day 26 postinfection to obtain high-dose-infected anti-M, pneumoniae sera. For the time course evaluation of hamster humoral immune response to mycoplasma infection, hamsters were intranasally inoculated with ~5 × l0 s CFU of wild type, virulent M. pneumoniae strain B25C. Hamsters were bled at 1, 2, 4, 8, and 12 wk postinfection. Rabbit anti-M, pneumoniae antiserum was obtained by subcutaneous and intramuscular injection of 10 x° CFU of wild type M. pneumoniae in Freund's complete adjuvant, followed three weeks later by a booster of 10 l° mycoplasmas in Freund's incomplete adjuvant. Blood was drawn 5-14 d after the booster injection.
Soluble-antigen RIP Assay. The RIP assay used for the identification of soluble M. pneumoniae immunogens was a modification (28) of the method of Baseman and Hayes (29) . Fresh or frozen radiolabeled myeoplasma pellets were resuspended in 250/~1 of 10 mM Tris-HC1 (pH 7.8), 0.2% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), 10 mM EDTA, and 1% (vol/vol) Triton X-100 (TDSET) (30) that contained 100 mM phenylmethylsulfonyl fluoride. The suspension was incubated at room temperature for 5 min, 20 #1 of ovalbumin (50 mg/ml) was added, and the suspension was incubated at 37°C for 15 min. This solution was then centrifuged over a cushion of 5% sucrose in TDSET at 100,000 g for 45 min to remove insoluble material. The supernatant was carefully removed and then diluted with TDSET to the desired volume. This soluble antigen preparation was divided into 100-/zl aliquots, and 20 /zl test antiserum was added. The antigen-antiserum mixtures were incubated at 37°C for 15 min before incubation at 4°C overnight. 50/~1 of a washed 10% suspension of formalin-treated protein A-bearing Staphylococcus aureus (Staph A) was added to each aliquot, and the suspensions were placed on a rocker platform for 90 min at 4°C. The Staph A, with adsorbed immune complexes, was washed four times with TDSET. The labeled, precipitated antigens were eluted by resuspending the Staph A pellet in 30/~1 of 0.1 M Tris-HCl (pH 6.8), 2% (wt/vol) SDS, 20% (vol/vol) glycerol, 2% (wt/vol) fl-mercaptoethanol, and 0.02% (wt/vol) bromophenol blue (SP buffer) (31) and boiling the suspension for 3 min. The Staph A was pelleted and the supernatant was subjected to SDS-polyacrylamide gel electrophoresis (PAGE).
Whole-Cell RIP Assay. Hansen et al. (32) have recently described an RIP procedure which permits identification of antibody-accessible proteins on the cell surface of pathogens. This procedure, which will be referred to as a whole-cell RIP assay, was used to identify surface immunogens of M. pneumoniae that are accessible to antibody in their native conformation. Briefly, [aSS]methionine-labeled M. pneumoniae were suspended in cold PBS, and 125-#1 aliquots of this suspension were mixed with 40/d test antisera. The suspensions were placed on a rocker platform for 90 min at 4°C to allow antibody binding to accessible mycoplasma surface proteins. The mycoplasmas were pelleted in a Microfuge B (Beckman Instruments, Inc., Palo Alto, CA) and washed once with PBS to remove unadsorbed antibody. The organisms were resuspended in 1.0 ml TDSET, vortexed, and incubated at 37°C for 1 h (with periodic vortexing to ensure efficient solubilization). Insoluble material was removed by centrifugation at 45,000 g for 1 h. The uppermost 0.9 ml of supernatant was carefully transferred to another tube, and 250/d of washed Staph A was added to each supernatant. The suspensions were placed on a rocker platform and incubated for 90 min at 4°C. The Staph A was washed four times with TDSET, and adsorbed M. pneumoniae surface immunogens were eluted in 35 p.l SP buffer, as described above, before SDS-PAGE.
Trypsin Treatment of Intact M. pneumoniae. Intrinsically labeled ([aSS]methionine) M. pneumoniae
was resuspended in 100/d PBS, and 5.0 #g trypsin (type XI; Sigma Chemical Co., St. Louis, MO) was added. The suspensions were incubated at 37°C for 10 min, and the enzymatic reaction was stopped by the addition of 10 ~g trypsin inhibitor (type II-0; Sigma Chemical Co.). After incubation for 10 rain at 0°C, the trypsin-treated mycoplasmas were used in a whole-ceU RIP assay.
SDS-PAGE and Fluorography.
One-dimensional SDS-PAGE was performed according to Laemmli (33) , using a 1.5-mm slab consisting of a 3% stacking and 7.5% separating gel. 14C-labeled molecular weight standards (Bethesda Research Laboratories, Rockville, MD) were myosin (200,000), phosphorylase b (92,500), bovine serum albumin (68,000), ovalbumin (43,000), and ehymotrypsinogen (25, 700) . Upon completion of electrophoresis, the slab was placed in fixative (methanol/acetic acid/H20, 45:10:45) overnight. The gel was then processed for fluorography according to the method of Bonner and Laskey (34) . fection are proteins with a p p a r e n t molecular weights of 165,000 and 110,000. W h e n h u m a n acute and convalescent sera are assayed by R I P ( " H u m a n A / C " ) , the resultant precipitation patterns are r e m a r k a b l y similar to those produced by pre-and postinfection hamster sera. E x a m i n a t i o n of paired antisera by R I P revealed that the majority of infected hamster and h u m a n sera precipitated the 165,000 protein during convalescence only. However, the 110,000 protein, which was also precipitated by a majority of postinfection hamster sera, was precipitated poorly, if at all, by convalescent h u m a n sera. W h e n 15 serum samples o b t a i n e d from patients who did not have M. pneumoniae were tested in the R I P assay, none precipitated the 165,000 or 110,000 protein (data not shown). T h e 165,000 protein co-migrates on S D S -P A G E with protein P1, and the 110,000 protein co-migrates with protein P2, both of which have been previously described by us (3). Proteins P1 and P2 have been localized on the surface of M. pneumoniae by 125I-labeling and are sensitive to brief trypsin treatment of intact mycoplasmas (3, 35) . In addition, P1 a n d P2 b i n d in vitro to respiratory epithelial cells (35) .
Results

Soluble-antigen RIP of Hamster and Human
Whole-Cell RIP. I m m u n o g e n s that elicit host protective a n t i b o d y in vivo are commonly exposed at the surface of the pathogen and are accessible to antibody. T h e whole-cell R I P assay permitted identification of antibody-accessible immunogens on intact M. pneumoniae (Fig. 2) . T h e first lane is a total [35S]methionine-labeled M. pneumoniae protein profile, and the second lane shows the b i n d i n g of labeled antigens to Staph A in the absence of antiserum. T h e next pair of lanes is representative of whole-cell R I P patterns p r o d u c e d by pre-bleed and postinfection (day 26, high-dose inoculation) hamster sera, whereas the last two lanes are representative of whole-cell precipitation patterns obtained with h u m a n acute and convalescent sera. T h e paired sera from hamsters and h u m a n s yield almost identical whole-cell R I P profiles. Note The second lane is the whole-cell RIP assay with no serum control. The remaining lanes are representative whole-cell RIP profiles of paired pre-bleed and high-dose infection hamster sera and paired acute and convalescent human sera, as indicated. Molecular weight markers (K = 103) and proteins P1 and P2 are indicated to the right. the decreased precipitation of labeled m y c o p l a s m a proteins by hamster preinfection and h u m a n acute sera when the whole-cell (rather than the soluble-antigen) R I P assay is used. Also, hamster and h u m a n convalescent sera strongly precipitate both proteins P1 and P2 in the whole-cell R I P assay, in contrast to the h u m a n convalescent precipitation pattern detected by the soluble-antigen R I P (Fig. 1) . pneumoniae should produce a precipitation pattern very similar to that derived from a soluble-antigen RIP employing lactoperoxidase-catalyzed, radioiodinated intact M.
Intrinsically Labeled
pneumoniae. Fig. 3 presents such a comparison. Although the intrinsically and extrinsically labeled M. pneumoniae total protein profiles are significantly different, the precipitation of p r e d o m i n a n t surface immunogens with either method ([35S]methionine whole-cell or x2~I-soluble-antigen RIP) is nearly identical. These results confirm the selective precipitation of surface proteins by the whole-cell R I P assay and indicate that detergent solubilization does not adversely affect a n t i b o d y recognition of M.
pneumoniae antigens.
Whole-Cell RIP of Trypsinized M. pneumoniae. Brief trypsin treatment of intact mycoplasmas will remove proteins P1 and P2 from the surface of the mycoplasmas (3) and thus should abolish precipitation of these proteins by convalescent sera in a whole-cell R I P assay. Comparison of control and trypsin-treated [ZSS]methioninelabeled M. pneumoniae total protein profiles revealed that the b a n d that co-migrates with protein P1 is removed upon trypsinization, whereas the b a n d that co-migrates with protein P2 is reduced in intensity (Fig. 4) . Convalescent h u m a n sera no longer precipitate either protein P1 or P2 (or other minor immunogens; see Figs. 2 and 3) when intact mycoplasmas are trypsin treated before use in a whole-cell R I P assay. The complete removal of P2 precipitation by a n t i b o d y suggests that the residual protein at 110,000 remaining after trypsin treatment is p r o b a b l y another protein of the same or similar molecular weight. 
Time Course Evaluation of Human and Hamster Serological Response to Infection. T o
f u r t h e r e x a m i n e t h e host h u m o r a l response to M. pneumoniae, s e q u e n t i a l s e r u m s a m p l e s o b t a i n e d from p a t i e n t s or i n f e c t e d h a m s t e r s were e x a m i n e d b y a s o l u b l e -a n t i g e n R I P (Figs. 5 a n d 6). I n h u m a n p a t i e n t s , a n t i b o d y to P 1 i n c r e a s e d a n d t h e n d e c r e a s e d w i t h t i m e (Fig. 5) . N o t e t h a t p a t i e n t s A a n d C also d e m o n s t r a t e d a selective a n t i b o d y response to p r o t e i n P2 a n d a p r o t e i n w i t h a m o l e c u l a r w e i g h t of ~ 70,000 t h a t followed t h e s a m e kinetics as t h e a n t i -P 1 response.
H a m s t e r s i n f e c t e d w i t h w i l d t y p e M.
pneumoniae s t r a i n B 2 5 C similarly s h o w e d a n increase in a n t i -P 1 a n t i b o d y as t h e infection progressed, followed by a decrease with time (Fig. 6) . The anti-P2 response maximized slightly later than the anti-P1 response, but remained high through 12 wk postinfection.
RIP Using other Mycoplasma Species.
The oropharynx of most humans is colonized with at least one mycoplasma species (36) . It is possible that this normal flora stimulates a host immune response that is cross-reactive with M. pneumoniae antigens.
To examine this possibility, M. salivarium and M. orale were radioiodinated and tested in the soluble-antigen RIP assay with rabbit anti-M, pneumoniae antiserum. The total protein and RIP patterns were compared with those of M. pneumoniae strain B 15 (Fig.   7) . The iodinated protein profiles of the three mycoplasma species were very dissimilar. Neither oral mycoplasma possessed proteins that co-migrate with protein P1 or P2.
Anti-M. pneumoniae serum precipitated all iodinated strain B 15 proteins but recognized no M. orale or M. salivarium proteins. These data demonstrate that there is little crossreactivity between oral mycoplasmas and M. pneumoniae and further suggest that RIP analysis of convalescent sera detects a specific immune response to M. pneumoniae.
Discussion
Several M. pneumoniae proteins have been associated with cytadsorption and virulence (3, 23, 24, 28, 37) , which implies that these maeromolecules play an essential role in successful parasitism. The host immunologic response to mycoplasma pneumonia may be directed against such attachment factors or virulence-specific proteins.
Although the literature suggests that M. pneumoniae stimulates cellular, humoral, and secretory immune responses (13, 18, (38) (39) (40) (41) , we chose to examine the host humoral response to specific mycoplasma proteins. The RIP technique, previously shown to be a powerful tool for analyzing the immune response to proteinaceous immunogens of pathogens (29, 30, 32, (42) (43) (44) , was used to examine acute and convalescent human and hamster sera. Preinfection hamster and acute human sera usually precipitate a small number of mycoplasma proteins in the soluble-antigen RIP assay. This precipitation may be due to cross-reactive antibodies or may result from a nonspecific binding of labeled mycoplasma proteins to Staph A that is mediated by nonimmunoglobulin serum components. For example, the 74,000 protein, which is weakly bound to Staph A in the absence of antiserum, shows enhanced precipitation in the presence of many serum samples tested. When the whole-cell RIP is used, precipitation of the 74,000 protein (and others) by serum is negligible, which indicates that this protein may be cytoplasmic. Whatever the reason for background precipitation of M. pneurnoniae proteins by preinfection and acute sera, this did not interfere with identification of immunogens based on increased precipitation of specific mycoplasma proteins by convalescent sera as compared with matched acute sera.
Proteins P1 and P2 elicit a strong antibody response during convalescence of both hamsters and humans infected with M. pneumoniae. The observed anti-P1 response is compatible with the immunogenicity of this protein (45) . Excellent correlation is shown between intrinsically labeled whole-cell RIP and extrinsically labeled solubleantigen RIP, which confirms the surface location of P1 and P2 and the selectivity of the whole-cell RIP assay (Fig. 3) . The epitopes of proteins P1 and P2 are apparently preserved in the detergent system used for solubilization of the mycoplasmas, and antigen-antibody complexes are readily formed and maintained in the presence of this detergent mixture. However, trypsin treatment, which removes P1 and P2 and destroys the attachment capability of M. pneumonme, does abolish precipitation of these predominant immunogens by convalescent sera in both the soluble-antigen and whole-cell assays (Fig. 4 and data not shown). This suggests that most, if not all, immunogenic determinants of P1 and P2 are available at the surface of the organism. One potential shortcoming of the RIP technique is that an immunogen that is insoluble in the detergent system used would not be detected. Although this possibility cannot be ruled out, the similarity of the TDSET-soluble [35S]methionine-labeled M.
pneumoniae profile (Fig. 1) to the total intrinsically labeled protein profile (Fig. 2) indicates that excellent solubilization of the mycoplasmas has occurred.
The RIP data obtained from sequential serum samples drawn from military recruits with mycoplasma pneumonia (Fig. 5 ) and experimentally infected hamsters (Fig. 6) indicate that anti-P1 antibody is formed in response to M. pneumoniae infection, but the level of anti-P1 in the serum decreases with continuing convalescence. The hamster anti-P2 response, in contrast, remains strong throughout 12 wk postinfection. Also, the hamster anti-P2 precipitate seems to maximize later than the hamster anti-P1 precipitate (Fig. 6) . In some recruit sera, another protein with a molecular weight of ~70,000 is recognized concomitantly with P1 and P2. The observed precipitation of additional proteins by certain human sera appears to be the result of a quantitative, rather than a qualitative, phenomenon, since in a whole-cell RIP using recruit sera, the precipitation of P2 and the 70,000 protein is greatly enhanced (data not shown).
The RIP technique has demonstrated a specific host humoral immune response to certain M. pneumoniae proteins. Two predominant immunogens, proteins P1 and P2, stimulate an antibody response only during convalescence of humans and hamsters. These proteins do not have correlates in two common oral mycoplasmas, and anti-M.
pneumoniae antiserum does not precipitate proteins derived from such oral mycoplasmas, which further suggests that anti-P1 and anti-P2 are specifically produced in response to M. pneumoniae infection. These data, plus the absence of any false positive anti-P1 or anti-P2 responses in a normal population or in patients hospitalized for other illnesses (data not shown), suggest that proteins P1 and P2 may be useful in serodiagnosis of mycoplasma pneumonia. Clinical diagnosis of mycoplasma pneumonia is usually based on a fourfold rise in the CF titer over a 3 wk period (9) . The CF test detects antibody directed against lipid determinants extracted from M. pneumoniae (9, 10) . However, this lipid antigen cross-reacts with many plant and animal glycolipids (9, 46) . In addition, patients with pancreatitis demonstrate high titer antibody against this M. pneumoniae lipid antigen (47) . These known potential sources of false positive CF reactions have only emphasized the need for a serodiagnostic test that measures antibody to a specific component of M. pneumoniae. The data reported herein suggest that, for instance, an enzymelinked immunosorbent assay using proteins P 1 and P2 as target antigens may provide an improved method for serodiagnosis of mycoplasma pneumonia.
Proteins P1 and P2 would appear to be logical components of an M. pneumoniae vaccine. However, controversy over the role of serum antibodies in natural disease remains unsettled (14, 16, 18, 40, 48) . Experiments currently underway in this laboratory will evaluate whether anti-P1 and anti-P2 antisera have any biological effect (bactericidal, opsonic, anti-attachment, etc.) on virulent M. pneumoniae. Such data should indicate the efficacy of P 1 and P2 as vaccine candidates. It is noteworthy that human and hamster sera examined by RIP consistently demonstrate a response to proteins P1 and P2, even though these subjects were probably infected with different strains of M. pneumoniae. This observation further suggests the feasibility of using P 1 and P2 as tools in serodiagnosis and vaccine development.
Summary
The immune response of experimentally infected hamsters and human patients to Mycoplasma pneumoniae was examined by radioimmunoprecipitation in conjunction with gel electrophoresis and fluorography. Both intrinsically and extrinsically labeled mycoplasma proteins were coincubated with acute and convalescent sera in a radioimmunoprecipitation assay. Two M. pneumoniae proteins were selectively precipitated by convalescent sera. These predominant immunogens were trypsin-sensitive, antibodyaccessible surface proteins that co-migrate on polyacrylamide gels with proteins P 1 and P2, which were previously implicated by us as mediators of cytadsorption. Anti-M. pneumoniae antiserum did not precipitate radiolabeled antigens derived from Mycoplasma orale or Mycoplasma salivarium. These data indicate that M. pneumoniae infection stimulates a specific and highly targeted host antibody response to key proteinaceous immunogens.
